TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31638920

Group type: COMPARATOR
Intervention: Control group participants in a randomized controlled trial (specific intervention details not provided)
Number of subjects: 0
Study: 28729250

Group type: EXPERIMENTAL
Intervention: DCB (Drug-Coated Balloon)
Number of subjects: 300

Group type: COMPARATOR
Intervention: PTA (Percutaneous Transluminal Angioplasty)
Number of subjects: 300
Study: 29083391

Group type: EXPERIMENTAL
Intervention: Maitland mobilization and lumbar stabilization exercises
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional physical therapy (traction, strengthening, stretching exercises)
Number of subjects: 30
Study: 23284039

Group type: EXPERIMENTAL
Intervention: Complete resection before chemotherapy
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Incomplete resection before chemotherapy
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Biopsy or no surgery before chemotherapy
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Complete resection after induction chemotherapy
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Incomplete resection after induction chemotherapy
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Biopsy or no surgery after induction chemotherapy
Number of subjects: 278
Study: 21440999

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 393
Study: 18851852

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2 g of elemental calcium)
Number of subjects: 524

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 524
Study: 16728220

Group type: EXPERIMENTAL
Intervention: Angiographic adverse events during PCI
Number of subjects: 6010

Group type: EXPERIMENTAL
Intervention: Occurrence of angiographic adverse events
Number of subjects: 6010

Group type: EXPERIMENTAL
Intervention: Side branch closure, abrupt closure, decreased flow, distal embolization, perforation or tamponade
Number of subjects: 6010
Study: 16281880

Group type: EXPERIMENTAL
Intervention: 10 mg isotretinoin + 0.05% tretinoin cream
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 20 mg isotretinoin + 0.05% tretinoin cream
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 0.5 mg isotretinoin/kg bodyweight + 0.05% tretinoin cream + oral methylprednisolone
Number of subjects: 28

Group type: COMPARATOR
Intervention: 0.5 mg isotretinoin/kg bodyweight + 0.05% tretinoin cream
Number of subjects: 28
Study: 11724639

Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg acute, titrated to 16 mg daily chronic)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Candesartan (chronic)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Candesartan (acute and chronic)
Number of subjects: 21
Study: 9390536

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 2306

Group type: EXPERIMENTAL
Intervention: Methotrexate, fluorouracil, and tamoxifen (MFT)
Number of subjects: 2306

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, methotrexate, fluorouracil, and tamoxifen (CMFT)
Number of subjects: 2306
Study: 8203874

Group type: EXPERIMENTAL
Intervention: 12 hours of bed rest post-cardiac catheterization
Number of subjects: 0

Group type: COMPARATOR
Intervention: 6 hours of bed rest post-cardiac catheterization
Number of subjects: 0
Study: 2658575

Group type: EXPERIMENTAL
Intervention: SMS-201-995
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31482417

Group type: EXPERIMENTAL
Intervention: Gentamicin 2.5 mg/kg every 12 hours (Group 1)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Gentamicin 4 mg/kg every 36 hours (Group 2)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No Gentamicin therapy (Group 3)
Number of subjects: 56
Study: 28279833

Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg sc weekly for 26 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no mipomersen)
Number of subjects: 15
Study: 25576052

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study: 23466551

Group type: EXPERIMENTAL
Intervention: Anti-stigma films (intervention group)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 43
Study: 21736454

Group type: EXPERIMENTAL
Intervention: High-confidence trials during source memory task (MTL region)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-confidence trials during item memory task (MTL region)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Source memory tasks (PFC region)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-confidence activity in both tasks (PFC region)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-confidence activity (Parietal region)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-confidence activity (Parietal region)
Number of subjects: 0
Study: 18647298

Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tolterodine ER 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 16225841

Group type: EXPERIMENTAL
Intervention: Task Concentration Training (TCT)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Task Concentration Training (TCT) combined with Cognitive Therapy (CT)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Task Concentration Training (TCT) or TCT-CT
Number of subjects: 65

Group type: COMPARATOR
Intervention: Applied Relaxation (AR)
Number of subjects: 65
Study: 12629444

Group type: EXPERIMENTAL
Intervention: Two-week exercise and diet program
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Continued exercise training at home for seven adolescents
Number of subjects: 14

Group type: COMPARATOR
Intervention: Diet alone (control group)
Number of subjects: 14
Study: 10718895

Group type: EXPERIMENTAL
Intervention: Training group (3-hour 'train-a-trainer' workshop)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manual-only group (mailed nutrition manual)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 8885210

Group type: EXPERIMENTAL
Intervention: Personal trainer intervention (regular calls and scheduled walks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lottery incentive for exercise adherence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 0
Study: 1545669

Group type: EXPERIMENTAL
Intervention: Gd-DOTA (0.1 mmol/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no Gd-DOTA)
Number of subjects: 20
Study: 4045017

Group type: EXPERIMENTAL
Intervention: Aerobic training program (30-minute continuous walk/jog, 3 days/week at 70-85% heart rate)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Aerobic training program
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (sedentary)
Number of subjects: 36
Study: 30211752

Group type: EXPERIMENTAL
Intervention: Mechanistic Concept Maps (MCMs) intervention (n = 43)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control groups (n = 127)
Number of subjects: 170
Study: 28464491

Group type: EXPERIMENTAL
Intervention: No IDUC
Number of subjects: 131

Group type: COMPARATOR
Intervention: IDUC
Number of subjects: 131
Study: 27504532

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) applied to one side of the jaw
Number of subjects: 20

Group type: COMPARATOR
Intervention: Peripheral blood (PB)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mandibular bone marrow with ESWT (BM + SW)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mandibular bone marrow without ESWT (BM - SW)
Number of subjects: 20
Study: 24694746

Group type: EXPERIMENTAL
Intervention: 600 kcal per session
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 400 kcal per session
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control
Number of subjects: 92
Study: 22666779

Group type: EXPERIMENTAL
Intervention: Ringer lactate (group RL)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES) (130/0.4) (group HES)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 4% succinylated gelatin (gelofusine solution) (group JEL)
Number of subjects: 75
Study: 20173364

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 64
Study: 18548234

Group type: EXPERIMENTAL
Intervention: 14-mg transdermal nicotine patch
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 22
Study: 15709546

Group type: EXPERIMENTAL
Intervention: Preoperative oral immunonutrition for 5 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment (no supplementation)
Number of subjects: 0
Study: 12408922

Group type: EXPERIMENTAL
Intervention: Formulation R (400 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Formulation T (400 mg)
Number of subjects: 6
Study: 10353452

Group type: EXPERIMENTAL
Intervention: Intensive case management (ICM)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Standard case management
Number of subjects: 73
Study: 7497762

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (800 micrograms/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 30
Study: 1784501

Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltration (0.25% with epinephrine 1:200,000)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal saline infiltration (with epinephrine 1:200,000)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltration
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal saline infiltration
Number of subjects: 14
Study: 6120713

Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Astemizole (10 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Astemizole (20 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Triprolidine (10 mg)
Number of subjects: 6
Study: 31533762

Group type: EXPERIMENTAL
Intervention: Behavioral design interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard vector control campaign methods
Number of subjects: 0
Study: 27917488

Group type: EXPERIMENTAL
Intervention: Building a Healthy Me (BHM) nutrition intervention
Number of subjects: 414

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 414
Study: 26084668

Group type: EXPERIMENTAL
Intervention: Sitagliptin (50 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Voglibose (0.6 mg/day)
Number of subjects: 100
Study: 24867891

Group type: EXPERIMENTAL
Intervention: Manual thrombus aspiration (TA)
Number of subjects: 1498

Group type: COMPARATOR
Intervention: Non-thrombus aspiration
Number of subjects: 1498
Study: 21733185

Group type: EXPERIMENTAL
Intervention: Intra-operative use of the 3D-RX system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional 2D-fluoroscopy
Number of subjects: 0
Study: 19204211

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 16996

Group type: COMPARATOR
Intervention: Inhaled corticosteroids vs placebo
Number of subjects: 16996

Group type: COMPARATOR
Intervention: Inhaled corticosteroids and long-acting β-agonists vs long-acting β-agonists
Number of subjects: 16996
Study: 17673732

Group type: EXPERIMENTAL
Intervention: Systematic screening (invitation for electrocardiography)
Number of subjects: 14802

Group type: EXPERIMENTAL
Intervention: Opportunistic screening (pulse taking and invitation for electrocardiography if the pulse was irregular)
Number of subjects: 14802

Group type: COMPARATOR
Intervention: Control practices (no active screening)
Number of subjects: 14802
Study: 14769141

Group type: EXPERIMENTAL
Intervention: Plasma exchange plus conventional cancer chemotherapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Plasma exchange plus continuous oral cyclophosphamide
Number of subjects: 20
Study: 11465968

Group type: EXPERIMENTAL
Intervention: Bisoprolol therapy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 112
Study: 9682351

Group type: EXPERIMENTAL
Intervention: PRP‐OMP
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: HbOC
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: PRP‐T
Number of subjects: 102
Study: 7527328

Group type: EXPERIMENTAL
Intervention: Lacidipine 2 to 8 mg/day for 1 to 4 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lacidipine 4 to 6 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 0
Study: 3205405

Group type: EXPERIMENTAL
Intervention: Pulsed magnetic stimuli applied over the scalp during tonic discharge of single hand muscle motor units (MUs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pulsed magnetic stimuli applied over the scalp
Number of subjects: 0
Study: 29792533

Group type: EXPERIMENTAL
Intervention: Resilience and Adjustment Intervention (RAI), delivered in seven 1-h sessions
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Resilience and Adjustment Intervention (RAI)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 160
Study: 29163341

Group type: EXPERIMENTAL
Intervention: Transcranial pulsed current stimulation (tPCS) alone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS) combined with tPCS
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) alone
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 6
Study: 25765827

Group type: EXPERIMENTAL
Intervention: Berberol(®)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study: 23070789

Group type: EXPERIMENTAL
Intervention: Flavonoid-rich juice (JUICE) 16 fl oz (230 mg flavonoids) ingested pre- and postworkout for 10 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nonathletic controls (n = 7)
Number of subjects: 9
Study: 20462577

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound (TVS)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Saline infusion sonohysterography (SIS)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Diagnostic hysteroscopy (DH)
Number of subjects: 105
Study: 18405345

Group type: EXPERIMENTAL
Intervention: Two-component motivational intervention based on the Theory of Planned Behaviour and volitional action planning
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Dispensing medication packaged in the electronic medication-monitoring device
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional medication packaging
Number of subjects: 200
Study: 17855795

Group type: EXPERIMENTAL
Intervention: FOLFIRI followed by docetaxel/cisplatin (arm A)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Mitomycin C (MMC) monochemotherapy (arm B)
Number of subjects: 169
Study: 12588788

Group type: EXPERIMENTAL
Intervention: GHEX (rHGH + exercise)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: SALEX (saline + exercise)
Number of subjects: 44

Group type: COMPARATOR
Intervention: GH (rHGH without exercise)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Saline (without exercise)
Number of subjects: 44
Study: 11139916

Group type: EXPERIMENTAL
Intervention: Dual-site RA pacing at AV interval of 100 ms
Number of subjects: 9

Group type: COMPARATOR
Intervention: High RA pacing at AV interval of 200 ms
Number of subjects: 9

Group type: COMPARATOR
Intervention: High RA pacing at AV interval of 50 ms
Number of subjects: 9
Study: 9097297

Group type: EXPERIMENTAL
Intervention: d,l-fenfluramine (60 mg p.o.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CRH (100 micrograms i.v.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8331682

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 22071

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22071
Study: 3080695

Group type: COMPARATOR
Intervention: Acute intravenous TRH (500 mg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Chronic subcutaneous TRH (25 mg daily for 3 months)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (saline) in chronic studies
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo with norepinephrine in acute studies
Number of subjects: 41
Study: 29212602

Group type: EXPERIMENTAL
Intervention: Control‐Cric™ System
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: QuickTrach II™
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard open surgical technique
Number of subjects: 70
Study: 27741339

Group type: EXPERIMENTAL
Intervention: 4% 5-Fluorouracil cream once daily for 4 weeks
Number of subjects: 841

Group type: COMPARATOR
Intervention: 5% 5-Fluorouracil cream twice daily for 4 weeks
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: 4% 5-Fluorouracil cream once daily for 2 weeks
Number of subjects: 841
Study: 25040898

Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy (MET)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control education condition
Number of subjects: 139
Study: 22722705

Group type: EXPERIMENTAL
Intervention: Holistic goal setting
Number of subjects: 29

Group type: COMPARATOR
Intervention: Isolated goal setting
Number of subjects: 29
Study: 19897255

Group type: EXPERIMENTAL
Intervention: Home-based daily muscle training for 12 months
Number of subjects: 63

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 63
Study: 18509347

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 9995
Study: 15723739

Group type: EXPERIMENTAL
Intervention: Fish oil omega-3 fatty acids (3 g/d)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Fish oil omega-3 fatty acids (3 g/d) and olive oil (9.6 mL)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (soy oil)
Number of subjects: 43
Study: 12793996

Group type: EXPERIMENTAL
Intervention: 1-g aspirin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12545825

Group type: EXPERIMENTAL
Intervention: Chemotherapy + PA-MSHA vaccine
Number of subjects: 177

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 177
Study: 8806338

Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 153

Group type: COMPARATOR
Intervention: No drug therapy (Control)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Beta blockers and No drug therapy (Control)
Number of subjects: 153
Study: 1463414

Group type: EXPERIMENTAL
Intervention: 0.003% PhXA34 (1 microgram; n = 9)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 0.01% PhXA34 (3 micrograms; n = 10)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Vehicle (n = 10)
Number of subjects: 29
Study: 6698221

Group type: EXPERIMENTAL
Intervention: Fresh semen
Number of subjects: 381

Group type: COMPARATOR
Intervention: Cryopreserved semen
Number of subjects: 381
Study: 31957963

Group type: EXPERIMENTAL
Intervention: Intraaortic balloon pump (IABP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study: 29722146

Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole 4 hours before EST and then every 12 hours for 1 day, followed by high-dose oral esomeprazole for 10 days
Number of subjects: 125

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 125
Study: 26540314

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m²) and oxaliplatin (100 mg/m²) with panitumumab (6 mg/kg) for up to 12 cycles (arm A)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Gemcitabine (1000 mg/m²) and oxaliplatin (100 mg/m²) without panitumumab (arm B)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Subgroup analysis for intrahepatic cholangiocarcinoma treated with panitumumab
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Safety profile of arm A (panitumumab)
Number of subjects: 89
Study: 24213883

Group type: EXPERIMENTAL
Intervention: Beta-alanine supplementation
Number of subjects: 16

Group type: COMPARATOR
Intervention: High-intensity interval training (HIT)
Number of subjects: 16
Study: 22884381

Group type: EXPERIMENTAL
Intervention: Interval Training (IT) - cycling at 100% peak work rate for 30 seconds alternating with 30 seconds of rest
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous Training (CT) - cycling at 60% of peak work rate
Number of subjects: 60
Study: 20386070

Group type: EXPERIMENTAL
Intervention: bosentan (125 mg twice daily) and lopinavir/ritonavir (400/100 mg twice daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: lopinavir/ritonavir (400/100 mg twice daily)
Number of subjects: 12
Study: 18525036

Group type: EXPERIMENTAL
Intervention: Counseling program that encouraged abrupt weaning at 4 months
Number of subjects: 958

Group type: COMPARATOR
Intervention: Standard practice encouraging continued breast-feeding for as long as the women chose
Number of subjects: 958
Study: 15712076

Group type: EXPERIMENTAL
Intervention: 4.5% albumin
Number of subjects: 150
Study: 12088162

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 60
Study: 10206447

Group type: EXPERIMENTAL
Intervention: Metformin (1.5 to 2.25 g/d) for 6.1+/‐5.1 months
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Metformin (1.5 to 2.25 g/d)
Number of subjects: 43
Study: 8580383

Group type: EXPERIMENTAL
Intervention: RFLP‐A polymorphism of the interleukin 1 receptor type I gene (IL1RI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: RFLP‐B polymorphism of the interleukin 1 receptor type I gene (IL1RI)
Number of subjects: 0
Study: 2611735

Group type: EXPERIMENTAL
Intervention: Bereavement counselling
Number of subjects: 30
Study: 613552

Group type: EXPERIMENTAL
Intervention: Parenteral treatment with triamcinolone acetonide (Kenacort A) - 80 mg for the 1st and 2nd injections, 40 mg for the 3rd to 7th injections at two-week intervals
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Parenteral treatment with triamcinolone acetonide (Kenacort A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral treatment with prednisolone - initial dosage of 30 mg followed by reduced dosage for 6 months
Number of subjects: 40
Study: 31749182

Group type: EXPERIMENTAL
Intervention: Autologous graft
Number of subjects: 29

Group type: COMPARATOR
Intervention: Synthetic graft
Number of subjects: 29